Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
Stock Information
Featured Bugs
Aspergillus fumigatus
 more...
 
Welcome to Basilea
 
 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting.
 
Basilea owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections and severe skin diseases. The company's diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug in phase III (isavuconazole) as well as innovative earlier-stage programs. Toctino® (alitretinoin) is marketed in the United Kingdom, Denmark, France, Germany and Switzerland and is approved in Austria, Belgium, Canada, Finland, Luxemburg, the Netherlands and Spain. Toctino® has been recommended for approval in additional 16 European countries. Furthermore, a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™. Ceftobiprole is under regulatory review in the EU and several other countries.

Basilea has a fully integrated R&D organization and has set up commercial organizations in Canada, France, Germany, the Nordics, Switzerland and the United Kingdom, while it is building sales and marketing organizations in other countries to commercialize alitretinoin and to co-promote ceftobiprole, subject to approval.

 
News
 
 
Language
 
Monday, February 01. 2010
 
Basel, Switzerland, February 1, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces 2009 financial results reflecting first full year of Toctino® sales in its initial launch countries, and focused investments to support phase III development of isavuconazole globally and U.S. alitretinoin (Toctino®) trials. Combined cash and short-term investments amount to CHF 178.4 million as of December 31, 2009.
 
more...
 
Friday, January 29. 2010
 
Basel, Switzerland, January 29, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announces that based on a futility analysis of the isavuconazole phase III trial for the treatment of invasive Aspergillus infections, the Independent Data Safety Monitoring Board (IDSMB) has recommended the continuation of the study.
 
more...
 
Wednesday, December 30. 2009
 
Basilea Pharmaceutica Ltd. announces that the U.S. Food and Drug Administration (FDA) issued to the sponsor, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (Johnson & Johnson PRD), a Complete Response Letter on ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI).
 
more...
 
Monday, December 14. 2009
 
Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino® is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids.
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America
 
National Eczema Association
for Science and Education
 
Doctorfungus